Biocure Technology Inc. (CURE)
CNSX 
Summary
CURE Chart
CURE: Pullback In Healthcare Stocks Presents A Buying Opportunity
The Direxion Daily Healthcare Bull 3X ETF (CURE) has slipped in early 2026 as investors take profits after a strong performance in late 2025. The correction in healthcare stocks comes even as analysts envisage significant gains for CURE's ten largest holdings over the next 12 months. This dynamic may present an opportunity to rotate into CURE from the unlevereged XLV ETF, which tracks the same underlying index.
Which Sector Topped the Leaderboard for January Returns?
The first month of 2026 is already in the books. Which sector walked away with the top spot when it came to total returns?
CURE: Analysts Strike A Cautious Tone Heading Into 2026
The Direxion Daily Healthcare Bull 3X Shares ETF has meaningfully outperformed the S&P 500 so far in 2025, benefiting from a recent shift in sentiment toward health care stocks. While CURE's underlying index is not as cheap as it was a few months ago, it still offers a roughly 19% forward P/E discount relative to the S&P 500. After strong recent returns, analysts project modest single-digit gains over the next 12 months for CURE's largest holdings.
Biocure Technology Inc. (CURE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Biocure Technology Inc. ever had a stock split?
Biocure Technology Inc. Profile
| Capital Markets Industry | Financials Sector | - CEO | CNSX Exchange | CA09075T1075 ISIN |
| US Country | - Employees | 24 Mar 2026 Last Dividend | 20 May 2015 Last Split | - IPO Date |
Overview
This fund is designed for investors seeking aggressive investment exposure to the healthcare sector. By committing at least 80% of its net assets to financial instruments that offer 3X daily leveraged exposure to a specific index, the fund aims to amplify the returns of its underlying index on a day-to-day basis. The index in question is comprised of domestic companies operating within the healthcare sector. This includes a broad range of industries from pharmaceuticals and biotechnology to health care equipment, providers, and services. The fund's strategy is characterized by its non-diversified nature, focusing on maximizing the leveraged returns from this specific sector. It's crucial for potential investors to understand the inherent risks and rewards associated with leveraging, as it significantly magnifies both gains and losses depending on the daily index performance.
Products and Services
- 3X Daily Leveraged Exposure
This product is the cornerstone of the fund, aiming to triple the daily performance of its healthcare sector index. It's achieved through leveraging, a technique that uses financial instruments like futures and options to increase potential returns. Intended for experienced investors who are comfortable with high risk for the chance of high reward, this aggressive strategy highlights the fund's focus on capitalizing on short-term movements within the healthcare sector.
- Healthcare Sector Investments
The fund targets an array of industries within the healthcare sector, ensuring a focused yet comprehensive coverage. This includes investments in:
- Pharmaceuticals - Companies involved in the research, development, and marketing of medications.
- Health Care Equipment and Supplies - Firms that produce medical equipment, supplies, and devices for healthcare providers.
- Health Care Providers and Services - Entities that offer medical services directly to patients, ranging from hospital systems to specialized health services.
- Biotechnology - Companies focused on the technological application that uses biological systems or living organisms for the development of drugs, treatments, and therapies.
- Life Sciences Tools and Services - Organizations providing the necessary tools, services, and technologies for research and development in the life sciences field.
This diversified approach within the healthcare sector itself allows the fund to capitalize on various growth opportunities, from established pharmaceutical giants to emerging biotech innovators.
